| Literature DB >> 25101803 |
Hideki Ohmomo1, Tsuyoshi Hachiya2, Yu Shiwa1, Ryohei Furukawa1, Kanako Ono1, Shigeki Ito3, Yoji Ishida3, Mamoru Satoh4, Jiro Hitomi5, Kenji Sobue6, Atsushi Shimizu7.
Abstract
Transportation of samples is essential for large-scale biobank projects. However, RNA degradation during pre-analytical operations prior to transportation can cause systematic bias in transcriptome data, which may prevent subsequent biomarker identification. Therefore, to collect high-quality biobank samples for expression analysis, specimens must be transported under stable conditions. In this study, we examined the effectiveness of RNA-stabilizing reagents to prevent RNA degradation during pre-analytical operations with an emphasis on RNA from peripheral blood mononuclear cells (PBMCs) to establish a protocol for reducing systematic bias. To this end, we obtained PBMCs from 11 healthy volunteers and analyzed the purity, yield, and integrity of extracted RNA after performing pre-analytical operations for freezing PBMCs at -80°C. We randomly chose 7 samples from 11 samples individually, and systematic bias in expression levels was examined by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR), RNA sequencing (RNA-Seq) experiments and data analysis. Our data demonstrated that omission of stabilizing reagents significantly lowered RNA integrity, suggesting substantial degradation of RNA molecules due to pre-analytical freezing. qRT-PCR experiments for 19 selected transcripts revealed systematic bias in the expression levels of five transcripts. RNA-Seq for 25,223 transcripts also suggested that about 40% of transcripts were systematically biased. These results indicated that appropriate reduction in systematic bias is essential in protocols for collection of RNA from PBMCs for large-scale biobank projects. Among the seven commercially available stabilizing reagents examined in this study, qRT-PCR and RNA-Seq experiments consistently suggested that RNALock, RNA/DNA Stabilization Reagent for Blood and Bone Marrow, and 1-Thioglycerol/Homogenization solution could reduce systematic bias. On the basis of the results of this study, we established a protocol to reduce systematic bias in the expression levels of RNA transcripts isolated from PBMCs. We believe that these data provide a novel methodology for collection of high-quality RNA from PBMCs for biobank researchers.Entities:
Mesh:
Year: 2014 PMID: 25101803 PMCID: PMC4125218 DOI: 10.1371/journal.pone.0104283
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Workflow of the study design.
TaqMan probes for the 21 candidate genes analyzed by qRT-PCR.
| Gene symbol | Major alias | Gene name | TaqMan probe ID |
| GAPDH | – | Glyceraldehyde-3-phosphate dehydrogenase | Hs99999905_m1 |
| ACTB | β-Actin | Actin, beta | Hs99999903_m1 |
| IL1B | IL-1β | Interleukin 1 beta | Hs00174097_m1 |
| IL8 | IL-8 | Interleukin 8 | Hs00174103_m1 |
| IL10 | IL-10 | Interleukin 10 | Hs00174086_m1 |
| IL15 | IL-15 | Interleukin 15 | Hs01003716_m1 |
| IFNG | INF-γ | Interferon gamma | Hs00174143_m1 |
| TNF | TNFα | Tumor necrosis factor | Hs00174128_m1 |
| JUN | c-jun | Jun proto-oncogene | Hs99999141_s1 |
| HSPA1A | HSP70 | Heat shock 70-kDa protein 1A | Hs00359163_s1 |
| FOS | c-fos | FBJ murine osteosarcoma viral oncogene homolog | Hs01119267_g1 |
| NFKB1 | NFκβ | Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 | Hs00231653_m1 |
| TP53 | p53 | Tumor protein p53 | Hs00153340_m1 |
| NOS3 | ENOS | Nitric oxide synthase 3, endothelial cell | Hs01574659_m1 |
| SPI1 | PU.1 | Spleen focus-forming virus (SFFV) proviral integration oncogene | Hs00231368_m1 |
| CSF1R | CD115 | Colony-stimulating factor 1 receptor | Hs00911250_m1 |
| IL6 | IL-6 | Interleukin 6 | Hs00174131_m1 |
| SLC6A4 | – | Serotonin transporter | Hs00984349_m1 |
| HDAC5 | – | Histone deacetylase 5 | Hs00608366_m1 |
| NR3C1 | – | Glucocorticoid receptor | Hs00353740_m1 |
| BDNF | – | Brain-derived neurotrophic factor | Hs00542425_s1 |
RNA purity, yield, and integrity.
| Sample conditions | A260/A280 | RNA yield (µg) | RIN |
|
| |||
| Ctrl 1 | 1.96±0.06 | 2.91±1.44 | 9.56±0.22 |
| Ctrl 2 | 1.96±0.07 | 3.00±1.51 | 9.59±0.25 |
|
| |||
| Without stab | 1.97±0.06 | 2.93±1.16 | 8.44±1.00** |
| Later | 1.60±0.14*** | 0.31±0.08 | N.A. |
| Protect | 1.92±0.05** | 2.06±0.63 | 7.66±0.33*** |
| Lock | 1.99±0.04 | 1.73±0.62 | 9.57±0.31 |
| Shield | 1.87±0.10*** | 0.93±0.53 | N.A. |
| Stab | 2.02±0.04*** | 2.91±1.29 | 9.45±0.65 |
| SDS | 1.97±0.05 | 2.14±0.97 | 5.93±1.93*** |
| 1-Thio | 1.99±0.04** | 2.56±0.98 | 9.74±0.17 |
RNA purity, yield, and integrity were measured for 11 individual samples. A260/A280 indicates the ratio of absorbance at 260 and 280 nm.
N.A.: not available (not measureable), RIN: RNA integrity number.
*p<0.05; **p<0.01; ***p<0.001 (Wilcoxon signed rank test).
RNA yield could be measured for nine individual samples (failed in two samples).
RNA yield could be measured for 10 individual samples (failed in one sample).
Figure 2qRT-PCR analysis of 19 target transcripts.
GAPDH and the Ctrl1 condition were used as a reference transcript and condition, respectively. ΔΔCt values are shown by vertical axes. Horizontal axes represent pre-analytical conditions in the following order: Ctrl2, Without stab, Protect, Lock, Stab, SDS, and 1-Thio. *, p<0.05; **, p<0.01 (Wilcoxon signed rank test).
Figure 3Quality assessment and control of sequencing data from HiSeq2500.
A. Quality values of sequence reads calculated by Cufflinks (Cuffdiff) in each sample. B. The blue bars show the number of sequence reads mapped to the human genome (hs37d5) with TopHat, and the red line with squares indicates the mapped percentage in each sample (B).
Figure 4Data bias of transcriptome analysis in each condition.
A. Correlation analysis of the average of FPKM under eight conditions for each sample. B. Cluster analysis of 56 transcriptomes: eight conditions for each of seven volunteers. C. Pair-wise comparisons of significant differences in gene expression for each sample. The number in each box shows the number of differentially expressed genes (p<0.05, Wilcoxon signed rank test).
Figure 5Protocol to reduce systematic bias for transcriptome analysis of PBMCs collected in remote assessment centers.
A protocol for pre-analytical operations to mediate the effects of systematic bias in transcriptome data of PBMCs for transportation and biobanking is shown.